Compare LIQT & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LIQT | INTS |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Denmark | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 13.2M |
| IPO Year | 2011 | 2021 |
| Metric | LIQT | INTS |
|---|---|---|
| Price | $2.10 | $5.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.30 | ★ $38.00 |
| AVG Volume (30 Days) | 19.4K | ★ 27.8K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $42.12 | N/A |
| Revenue Next Year | $63.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.22 | $0.19 |
| 52 Week High | $3.35 | $8.06 |
| Indicator | LIQT | INTS |
|---|---|---|
| Relative Strength Index (RSI) | 61.96 | 42.17 |
| Support Level | $2.19 | $5.04 |
| Resistance Level | $2.56 | $8.06 |
| Average True Range (ATR) | 0.23 | 0.20 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 75.44 | 37.51 |
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in businesses that are liquid filtration market and the silicon carbide ceramic membrane & diesel particulate filter (DPF) market. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and others. Its operating segment includes Water, Ceramics, and Plastics.
Intensity Therapeutics Inc . is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.